Orilanolimab

**Semantic type:** Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance

**Definition:** A monoclonal antibody that targets the neonatal crystallizable fragment receptor (FcRn), with potential immunomodulating activity. Upon administration, orilanolimab targets and binds to FcRn at the immunoglobulin G (IgG) binding site, thereby preventing the interaction between FcRn and the serum protein IgG. By preventing FcRn/IgG binding, orilanolimab blocks the FcRn-mediated rescue of IgG, enables IgG degradation and prevents IgG-mediated inflammation. IgG plays a key role in many autoimmune diseases and is an important factor in inflammatory processes.

**Synonyms:** - Anti-FcRn Monoclonal Antibody SYNT001 - Immunoglobulin G4, Anti-(Human FcRn Receptor) (Humanized Monoclonal SYNT001 gamma4-Chain), Disulfide with Humanized Monoclonal SYNT001 kappa-Chain, Dimer - ORILANOLIMAB - SYNT 001 - SYNT-001 - SYNT001